Introduction
Antibodies are the core molecules of the immune system for identifying, targeting, and clearing pathogens from the infected organism. Immunoglobulin G( IgG), a1 50 kDa protein consisting of two heavy and two light chains is the predominant antibody type found in nature. [1] Since antibodies were used for the detection of rhesus factor immunization and to quantify the amount of insulin present in blood plasma, uncountable analytical applications have been developed.
[2] Thea bility to generate humanized and monoclonal antibodies highly specific to almost any antigen of interest has intensified this development and laid the foundation for the targeted therapeutic use of antibodies. [3] While early therapeutic concepts exclusively relied on the function of the antibody itself,more recent development combine the target specificity of antibodies with the effectiveness of small drug molecules in so-called antibody-drug conjugates (ADCs). [4] Fort his,adrug molecule is covalently linked to af unctional group within the antibody,w hich requires selective chemical methods for attachment without interfering with antibody function. [5] Thes ame trend of attaching functionality holds true for analytical and diagnostic antibodies.W hile many of the established methods rely on indirect detection modes like radioactive labelling of the antigen, oxidation by horseradish peroxidase,o rt he enzyme alkaline phosphatase (in enzymelinked immunosorbent assay,E LISA), [6] more recent developments have made use of small fluorescent labels that are covalently bound to the primary antibody. [7] Theg eneration, production, functionalization, and intracellular application of full-length antibodies can be challenging. Antibodies are posttranslationally glycosylated proteins and their function has been shown to be dependent on the attached glycans. [8] Furthermore,a ntibodies have ac omplex structure involving inter-and intramolecular disulfide bonds, which is vulnerable towards environmental changes,t he reductive milieu of the intracellular environment, and the attachment of payloads.M oreover,c onventional IgGs contain ah ighly conserved loop length for the antigen-binding domain (complementary determining regions,C DRs), which evolved to bind convex paratopes,thereby limiting the scope of potential antigens. [9] Fori nstance,t he receptor-binding domains of various pathogens have evolved as cavities,which prevents the binding of full length IgGs. [10] Consequently,novel classes of recombinant antigen-binding proteins that lack these limitations are on the rise. [11] Besides their reduced size and structural complexity,m any recombinant antigen-binding proteins (binders) can be produced in high amounts using eukaryotic and prokaryotic cells, Nanobodies can be seen as next-generation tools for the recognition and modulation of antigens that are inaccessible to conventional antibodies.Due to their compact structure and high stability,nanobodies see frequent usage in basic research, and their chemical functionalization opens the way towards promising diagnostic and therapeutic applications.Int his Review,c entral aspects of nanobody functionalization are presented, together with selected applications. While early conjugation strategies relied on the random modification of natural amino acids,m ore recent studies have focused on the sitespecific attachment of functional moieties.S uchtechniques include chemoenzymatic approaches,e xpressed protein ligation, and amber suppression in combination with bioorthogonal modification strategies.Recent applications range from sophisticated imaging and mass spectrometry to the delivery of nanobodies into living cells for the visualization and manipulation of intracellular antigens. 
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and based on their increased stability towards reductive conditions,c an be applied within cellular environments. [12] This opens avenues for live-cell detection and the manipulation of important intracellular processes with minimal impairment to the cell. In contrast, the use of full-length antibodies is often limited to extracellular targets and fixed or permeabilized tissues.These promising properties have led to the development of various classes of binders that are either immunoglobulin-derived or synthetic derivatives of completely different protein classes.N anobodies are noteworthy examples of recombinant antigen-binding proteins that are distinguished by unique physical properties and binding specificity. [7, 13] They are defined as single-domain variable fragments of camelid-derived heavy-chain antibodies (hcAb). Nanobodies are introduced in Section 2a nd discussed in comparison with other formats of recombinant binders.I n Section 3, an overview of nanobody generation and selection procedures is given, and in Section 4, selected applications of genetically encoded nanobodies in cellular biology and imaging are depicted. In Section 5, techniques for the chemical functionalization of nanobodies will be highlighted. Recent developments allow the generation of homogenous nanobody conjugates that have increased binding affinity and beneficial in vivo properties compared to their randomly functionalized equivalents. [14] Finally,i nS ection 6, advances in the cellular delivery of nanobodies and other binders will be reviewed.
Recombinant Antigen-Binding Proteins:
Nanobodies and Others
IgGs are the predominant isotype of immunoglobulins and consist of two identical heavy and two identical light chains that are covalently linked through disulfide bonds. [1] Thea ntigen is recognized through an interplay between the variable N-terminal domains of the heavy (V H )a nd the light (V L )chain and six CDRs (Figure 1a) . [8] Binders derived from IgGs can be classified as antigen-binding fragments (Fab,c a. 50 kDa), single-chain variable fragments (scFv,c a. 25 kDa,) and heavy-or light-chain single domains (V H or V L ,c a. 12.5 kDa). Faband scFv binders consist of both the V H and V L domain of the parental IgG,and retain the size and affinity of the area binding the antigen. Due to their reduced size compared to regular IgGs,t hey show enhanced pharmacokinetic properties for in vivo applications.
[10a] V H and V L are covalently linked by artificial amino acid linkers or disulfides and associated through strong hydrophobic interactions. Ward et al. were able to demonstrate,t hat functional single V H domains of mice can be secreted from E. coli,a nd they hypothesized that their reduced size should enable binding to the cavities of pathogens. [15] However, these expectations have not been fulfilled. Thea ntigen-binding area of isolated V H domains is bisected and their binding affinity significantly reduced compared to the parent antibody.M oreover,t he hydrophobic amino acids that are essential for V H /V L interaction in full-length IgGs are solvent-exposed, thus leading to aggregation and poor solubility. [7] In the early 1990s,a ne xceptional class of IgG immunoglobulin was detected in the sera of Camelidae.
[13a] These so called heavy-chain antibodies (hcAb) are devoid of light chains,w ith the functional antigen-binding unit reduced to asingle variable domain (V H H, Figure 1a ). [7, 16] These properties allow the generation of potent, recombinant V H Hs by isolating and engineering the corresponding single domain region of Camelidae Bc ells after immunization. Based on their small size of around 13-14 kDa, recombinant V H Hs are often referred to as nanobodies.I nterestingly,s imilar IgG derivatives have been identified in several cartilaginous fish (Ginglymostoma cirratum, Orectolobidae). [21] Thestructure of nanobodies differs in two ways from V H domains of regular IgGs.F irst, the CDRs are enlarged to provide as imilar antigen-interacting surface to that of regular IgGs (600-800 2 ,F igure 2). [22] These changes result in nanobodies binding their antigen in ac onvex paratope,t hus making them well suited for binding structures that are restricted for full-length IgGs like immune-evasive epitopes and cavities. [22, 25] Second, hydrophobic amino acids within the conserved framework region (FR) that are responsible for V H /V L interaction are replaced with hydrophilic amino acids. [26] In particular,t hese mutations contribute to the increased solubility and stability of nanobodies,t hus allowing asimplified manufacturing process and aw ide range of biotechnological applications. [27] Moreover,n anobody-based cancer therapy has revealed that nanobodies possess beneficial biophysical and pharmacological properties for in vivo applications,w ith indications for al ow response from the immune system, which is encouraging for future clinical trials. [28] Together,t hese unique properties of nanobodies have even initiated "camelization" strategies for human [17] b) Afibronectin-based monobody binding the SUMO protein (PDB ID:3 RZW). [18] c) An affibody based on Protein A, binding to HER 2(PDB ID:3MZW). [19] d) Al ibocalin derived anticalin binding to the Alzheimer'sdisease (AD)-relevanta myloid-b (PDB ID:4MVI). [20] e) Adesigned ankyrin repeat protein (DARPin) in complex with human interleukin-4 (PDB ID:4 YDY). Antigensa re shown in blue, antigen-binding proteins in gray. from Camelidae with GFP as the antigen (PDB ID:3 G9A). [17] b) A human derived variable domain (V H )w ith vasculare ndothelial growth factor as the antigen (PDB ID:2FJF). [23] V H Hs contain asignificantly enlarged CDR3 framework (black), thus ensuring high binding affinity. Several hydrophobic amino acids that are highly conserved in conventional V H domains are mutated within nanobodies, which increases their solubility (orange).
derived single V H to increase their binding affinity and stability while maintaining their low immunogenic potential in humans. [9b, 29] Alternatively,ahumanized nanobody scaffold has been engineered, which facilitates CDR grafting from other nanobodies for the development of nanobody based therapeutics. [30] Along these lines,pharmaceutical companies like the Belgian company Ablynx nv have agrowing number of pre-clinical and clinical programs in development that are based on proprietary nanobody technology,t hus further emphasizing their potential. [31] In addition to immunoglobulin-derived binders,n onimmunoglobulin-based proteins have been engineered to specifically bind antigens with similar affinity compared to conventional antibodies.S mall proteins that are involved in tight protein-protein interactions serve as scaffolds for the generation of such binders.T he specific binding surface of these scaffolds is randomized and high-affinity binders selected through an in vitro display technique. [32] Prominent examples are monobodies, [33] anticalins, [34] affibodies,a nd designed ankyrin repeat proteins (DARPins; [35] Figure 1b -e). Monobodies are recombinant antigen-binding proteins based on human fibronectin III. [33] They are structurally similar to immunoglobulin binders but devoid of intramolecular disulfides,t hus making them ideal for intracellular applications. [36] Thec ell wall protein Protein Ap resent in Staphylococcus aureus serves as the basis for affibodies. [37] In nature,P rotein Ab inds the fragment crystallizable (Fc) region of immunoglobulins,p reventing phagocytosis triggered by an immune response of the host organism. [38] Mutagenesis of the binding area resulted in an umber of efficient affibodies that bind targets like human insulin or the cytokine TNFa. [39] Anticalins are derived from the ß-barrelstructured lipocalins,adiverse class of proteins responsible for the transport, storage,s ynthesis,a nd sequestration of small hydrophobic molecules. [40] Lipocalin-based libraries have enabled the selection of anticalins against various targets with up to picomolar affinities. [34] Finally,D ARPins are based on natural ankyrin repeats that are involved in protein-protein interactions.I nc ontrast to other engineered binders,DARPins are characterized by amodular assembly of consecutive repeats engineered to bind as pecific target. [35] Thed ifferent classes of engineered recombinant antigenbinding proteins share many advantageous properties,including high stability and small size.However,the effort needed in generating non-Ig-derived recombinant antigen-binding proteins with sufficient binding affinity is high, thus limiting the applicability of these binders. [41] 3. Nanobody Generation and Selection Procedures Nanobodies (and other immunoglobulin-based recombinant antigen-binding proteins) can either be generated by immunizing the respective animal with the antigen of interest, [27] or by further evolving an existing naïve library. [42] In the case of immunization, up to six injections of around 0.5 mg antigen or immobilized antigen (e.g., BSA conjugate) are performed within at ime course of several weeks. [43] The mRNAi si solated from lymphocytes and its complementary DNA( cDNA) synthesized using reverse transcriptase. [16, 43] Next, the specific segment encoding the V H Hd omain is amplified and potent binders isolated or further engineered using ap olypeptide display technique.P hage display is the most common display technique for in vitro binder selection and is capable of screening up to 10 11 sequences per library. [44] Here,the V H Hencoding part is fused to aviral coat protein, leading to the library being displayed on the surface of bacteriophages.S ince each phage displays as ingle V H H variant and contains its genetic information, the most efficient binders can be selected by challenging the library with the immobilized antigen followed by nucleotide sequencing. Alternative screening strategies include yeast and bacterial display,i nw hich binders can be selected by multiparameter and quantitative flow cytometry,a swell as mRNAa nd ribosome display,w hich are well suited for the selection of large libraries of up to 10 15 sequences.
[44c] Once ap otent nanobody is selected, it can be readily expressed in high yields of up to several gL À1 in E. coli, S. cerevisiae, P. pastoris, or human cells by using ap eriplasmic leader sequence. [45] Secretion to an on-reducing environment during expression is advisable,s ince nanobodies harbor up to two disulfide bridges. [16] An overview of the nanobodies presented within this review,t ogether with their targets,f unctionalization approaches,a pplications,a nd known affinity values is given in Table 1 .
Genetically Encoded Nanobodies in Cellular Biology and Imaging
As already mentioned, nanobodies have advantageous properties for advanced applications in molecular biology. [7] They feature high thermal and conformational stability and retain their binding activity after prolonged incubation at elevated temperatures,h igh salt concentrations,a nd under different pH conditions.
[46] Moreover,t hey are able to efficiently refold and fully restore their antigen affinity after thermal denaturation, thus opening novel opportunities for studying the dynamics of protein folding. [41, 47] These robust properties allow them to capture their respective antigens in vitro as well as in vivo,o ne example being the widely used GFP binder. [27] Av isual example for antigen capture in living cells is the recently developed fluorescent-3-hybrid (F3H) assay to monitor dynamic protein-protein interactions (Figure 3a) . [48] Here,agreen fluorescent protein (GFP)-binding nanobody is fused to the Lac repressor, resulting in the recruitment of GFP fusion proteins to artificial LacO DNArepeats.Assoon as asecond protein labelled with another fluorescent molecule interacts with the GFP fusion, it will be co-recruited to the anchor site,thereby enabling time-resolved visualization of protein-protein interactions.
In recent years,n anobodies have been used to analyze protein function in living cells and organisms.T he reversible genetic knockdown of proteins by interfering RNAi s ap rominent method for elucidating protein function. However,s uch systems rely on the fast depletion of the target protein. An alternative method to study protein function by Solid support, randomly attached (NHS-chemistry), [b] TTL mediated chemoenzymatic biotinylation Immunization 0.23 [27] Detection of PPIs [,48a] Lac repressor,g enetic fusion Protein degradation [49] F-box domain of Slmb, genetic fusion Imaging [27, 65, 66, 72] FPs, genetic fusion;fluorophores and gold nanoparticlesrandomly attached (NHS-chemistry), chemoenzymatic TTL
[c] mediated sitespecific attachment Intracellular protein discovery [109] Polycationic resurfacing, FPs, [d] genetic fusion $1 [109] Cellular delivery,l ive cell immunostaining [118] Linear and cyclic cell-penetrating peptides via EPL [e] 0.32 [118] l-Plastin Trapping of inactivec onformation [50] V5-tag for purification, genetic fusion Immunization 40-80 [50] P-glycoprotein
Inhibitingdrug-effluxbased multidrug resistance [51] -I mmunization 520 [51] HypeE Inhibitingorstimulating AMPylation [52] Fluorophore, biotin, Sortase Amediated Naïve phage display library
Crystallization chaperone
[53c]
-I mmunization 1.6
EpsI:EpsJ Crystallization chaperone
Studying protein folding using NMR [54] -I mmunization and grafting CDRs to stable nanobodies 460 [54] Proclacitonin High-throughput assay [55b] Chitosane-graphene nanocomposite, randomly attached (glutaraldehyde) Immunization 6.2-24.5
[55b]
PCNA ImagingDNA replication [27, 60] FPs, genetic fusion Immunization N/A b-catenin Imagingofb-catenin [61] FPs, genetic fusion Immunization 1.9-44 [61] HIV-1 capsid protein ImagingHIV-1 [62] FPs, genetic fusion Immunization 0.16 [62] Nuclear lamina
Imagingthe cytoskeleton [27] FPs, genetic fusion Immunization
HER2
Biomarker for breast cancer
Radiolabel, engineered C-terminal cysteine & maleimide chemistry Immunization $6
[14a]
Biomarker for breast cancer [86a] Radiolabel, fluorphore, chemoenzymatic attachmentbythe use of Sortase A $4 [86a] Nanobody based activation immunotherapeutic [91] Dinitrophenyl moiety,c hemoenzymatic attachmentb ythe use of lipoic acid ligase 0.51-3.2 [120] Intracellular protein discovery [109] Polycationic resurfacing, FPs, genetic fusion $1 [109] CAIX Biomarker for breast cancer
Radiolabel, engineered C-terminal cysteine & maleimide chemistry Immunization 13 [75d] reversible knockout makes use of nanobodies that mediate ubiquitin-dependent protein degradation of the bound protein ( Figure 3b ). [49] This technology was used against aG FP fusion to show that the myosin II regulatory light chain Sqh is required for dorsal closure in the fruit fly Drosophila. Moreover,n anobodies have been used to sense and trap specific conformations of proteins. [17] Nanobodies that bind lplastin, an actin-binding protein involved in immune regulation, that trap the protein in an inactive conformation revealed that l-plastin plays an important role for immune synapse formation and T-cell proliferation. [50] Moreover, an anobody that was shown to inactivate the intracellular ATPh ydrolysis activity of Pgp,a nA BC-type transporter, could potentially serve as the basis for the development of new therapeutics to overcome drug resistance during cancer therapy (Figure 4) . [51] Furthermore,n anobodies have been shown to modulate the abundance of posttranslational modifications on proteins in living cells.T ruttmann et al. were able to engineer V H Hs that either inhibit or stimulate Huntington associated protein E( HYPE)-mediated AMPylation of proteins and used these tools to identify histones H2, H3, and H4 as new targets for HYPE. [52] Another important application of nanobodies is their use as crystallization chaperones for intrinsically disordered proteins and large molecular complexes.T he production of protein crystals with sufficient quality for X-ray crystallography of such proteins can be highly challenging,a nd cocrystallization with nanobodies has been shown to improve the crystallization behavior significantly.I nt his way,t he structures of disordered proteins like the addiction antidote MazE and the amyloidogenic b2-microglobulin, as well as the structure of alarge protein complex of EpsJ and EpsI that is involved in the secretion of proteins,h ave been solved. [53] In addition to their use as crystallization chaperones,nanobodies have been utilized as NMR probes to study protein structure and folding. [54] Finally,n anobodies have even been shown to bind challenging epitopes such as small molecules.T his has led, Biotin, chemoenzymatic attachmentbythe use of BirA Immunization 950
Unknown Immobilization [80] Biotin, chemoenzymatic attachmentbythe use of transglutaminase Unknown N/A Class II MHC Immune response imaging [86b, 87] Radiolabel, chemoenzymatic attachmentbyt he use of Sortase A. Double functionalization with fluorophore and radiolabel by the use of Sortase Ai ncombination with engineered C-terminal cysteine & maleimide chemistry
EGFR Imagingand photoinduced cross-linking [96] Fluorphore and PEG, amber suppression of AmAzZLys Immunization 11.5-14.1 [96] VCAM-1 Immobilization [98] Biotin, attachmentb yEPL Immunization N/A PlexinD1 Tumor targeting [100] Polymersomes, attached by EPL Naïve phage display library N/A b-lactamase Intracellular protein discovery [109] Polycationic resurfacing, FPs, genetic fusion Immunization $1 [109] [a] Protein-protein interactions. for example,t othe development of various nanobody-based high-throughput assays to identify and quantify clinically relevant biomarkers,i ncluding testosterone and proclacitonin. [55] Thef luorescent labelling of proteins has become one of the most important tools for visualizing and understanding cellular structures and intracellular processes.F luorescent proteins (FPs), like GFP,a re the most frequently used biosensors,a nd their fusion to ap rotein of interest enables the dynamic visualization of proteins of interest in living cells. [56] Even though genetic fusion to FPs is straightforward, their fluorescence properties,a sw ell as at endencyt owards photobleaching,l imit their spectroscopic use,a nd their possible impact to the biological function of the protein of interest is often underestimated. [57] To improve the spectroscopic properties of FP-tagged proteins of interest, Kirchhofer et al. developed GFP-binding nanobodies that are able to modulate the absorption properties of GFP by inducing structural changes in the environment of the chromophore (Figure 5a ). These changes stabilize GFP fluorescence in living cells and resulted in higher fluorescence sensitivity and spatial resolution. [17] Figure 4. The nanobody Nb592 binds to the ATP-binding cassette (ABC) transporterP -glycoprotein (P-gp) and inhibits its ATPase activity. a) Crystal structure of P-gp in complex with Nb592. The nanobody specifically binds to the nucleotide-binding domain 1( NBD1)o fP-gp. TMD = transmembrane domain. P-gp is shown in blue, Nb592 in gray (PDB ID:4 KSD). [51] b) Upon ATPbinding and dimerization of the NBDs, restructuring of the P-gp and its TMD occurs and the xenobiotic is transportedacross the cellular membraneand into the extracellular environment. Upon ATPhydrolysis and the release of ADP and Pi release, the P-gps ground state is restored. In contrast, once Nb592 is bound to NBD1, NBD dimerization,A TP complexation, and transportera ctivity is inhibited. Nevertheless,s everal studies have revealed that the genetic fusion of fluorescent proteins to ap rotein of interest can result in loss and even alteration of function. [59] Thec oexpression of an FP-tagged nanobody (so called chromobody) with high affinity to the protein of interest can serve as ap owerful alternative (Figure 5b ). As well as avoiding genetic manipulation of the target protein, its endogenous expression level is also retained, thereby increasing experimental authenticity. [27] In exchange,p ossible functional and structural changes upon antigen binding need to be examined and evaluated. Among others,c hromobodies have been developed for the live-cell imaging of endogenous DNA replication in human cells, [60] endogenous b-catenin, [61] HIV1infection, [62] cytoskeletal components [27] and the progression of apoptosis. [63] Moreover,nanobodies have shown beneficial characteristics for super-resolution microscopy ( Figure 5c ). Conventional detection reagents composed of ap rimary antibody and afluorescently labelled secondary antibody lead to high linkage errors and loss of resolution since the actual dye is removed from the target structure (up to 30 nm). Nanobodies have ad iameter of 2.5 nm and ah eight of approximately 4nm, which makes them better suited for high-resolution imaging of cellular structures. [24] Guizetti and co-workers used aG FP-binding nanobody to elucidate the abscission stages of human cells and identified contractile filament helices with ad iameter of 17 nm to be ac entral component of intercellular bridges. [64] Theg ain in resolution was demonstrated with super-resolution imaging of microtubules. [65] This concept of using nanobodies for better fluorescence signal and resolution in imaging experiments has subsequently been further developed by labelling nanobodies with small organic fluorophores and gold nanoparticles. [65, 66] In recent years,anumber of such methods to facilitate the development of binders with advanced properties have been developed. An overview is given in the following section, and applications of the resulting functionalized nanobodies are discussed.
Chemical and Enzymatic Functionalization of Nanobodies:C oncepts and Applications
Thec hemical labelling of nanobodies with fluorophores, their immobilization on solid supports,ortheir functionalization with recognition motifs,d elivery agents,a nd other chemical groups broadly expands their applicability for imaging,p roteomics,a nd novel therapeutic tools.W hile traditionally,n anobodies used in imaging are expressed fused to FPs like GFP and RFP,t he labelling of nanobodies with small organic probes is expanding their utility as tools for biological research, including in super-resolution imaging. [65, 66] Due to their low production costs and long-term stability,n umerous nanobodies have been immobilized on different matrices and been used for immunoaffinity chromatography. [67] This is of particular interest for state-of-theart mass spectrometry (MS)-based proteomics since such technologies require the efficient enrichment of defined targets from complex protein mixtures.I nt his context, immobilized nanobodies that specifically bind fluorescently labelled proteins has allowed the combinatorial analysis of protein-protein interactions,DNA methyltransferase activity, and histone-tail binding by fluorescent microscopy and mass spectrometry (Figure 6 ). [27, 46c, 68] 
Lys-Selective Functionalization
In first proof-of-principle studies,n anobodies were randomly labelled at solvent-exposed lysine residues by Nhydroxysuccinimide (NHS) ester containing fluorophores to give heterogeneous protein mixtures (Figure 7a) . [65, 69] Similarly,N HS-functionalized matrices have been used to covalently attach and immobilize nanobodies. [66, 70] Even though Figure 5 . Nanobodiesi nimaging. a) Upon binding of its antigen, the GFP-bindingnanobody GBP stabilizes and enhances the fluorescence signal of GFP when imaged in living cells. The nanobody (V H H) is depicted in gray,GFP in green (PDB ID:3K1K [17] ). b) FP-tagged nanobodies (so called chromobodies) avoid the need for FP fusion to the protein of interest and maintain its endogenous expression level. Various chromobodies have been engineereda nd used as powerful imaging tools. The nanobody (V H H) is depicted in gray,GFP in green (PDB ID:3 G9A). [17] c) Nanobodieshave the ability to minimize linkage errors during super-resolution microscopyexperiments. They significantly reduce the spatial distance to the actual specimen compared to classical experimental setups composed of full-length primary and secondary antibodies. The nanobody is depicted in gray (PDB ID: 3G9A [17] ), the secondary and primary antibodies in gray and orange, respectively (PDB ID:1 IGT [58] ).
the unselective lysine labelling of nanobodies has proven valuable,ithas been shown to affect the CDR loops,leading to as ignificant reduction in epitope recognition.
[14b]
Moreover,t hese conventional bioconjugation technologies have proven unfavorable for in vivo therapy and diagnostics since unselective functionalization of antigenbinding proteins leads to variations in the number of probes attached, which, in combination with alteration of epitope recognition, can lead to impaired pharmacokinetic properties and stability.
[4b,c, 71] Therefore,t he site-specific attachment of tracers and drugs to nanobodies to give homogenous conjugates with adefined number of probes per binder can offer advantageous properties.P latanova and co-workers gained higher conjugation control by genetically adding apoly-lysine stretch to the Cterminus of GFP-and RFP-binding nanobodies (Figure 7b) . [72] Incubating the nanobodies with NHSactivated fluorophores resulted in al abeling ratio of 1.0-1.5 fluorescent molecules per nanobody.H owever,w hether the poly-lysine stretch prevented fluorophore conjugation to e-amino groups within the nanobody sequence was not shown and seems unlikely.I nr ecent years,an umber of methods for the site-specific functionalization of proteins have been applied to homogeneously modify nanobodies. These methods include selective modification of unpaired cysteine residues,chemoenzymatic systems,e xpansion of the genetic code,and expressed protein ligation (EPL).
Labeling of (Unpaired) Cysteine Residues
Increased homogeneity of protein conjugates can be achieved by addressing cysteine residues,w hich are less abundant in comparison to lysine. [73] In this case,the free thiol group of ar educed cysteine is converted with ac ysteineselective chemical entity carrying the probe or drug. Among others,m aleimides are the most common functional groups used for the labelling of cysteines. [74] However, since proteins often contain several cysteine residues that are involved in the formation of interchain disulfide bonds,a na dditional reduction step is required and the resulting conjugates are once again heterogeneous mixtures.T he introduction of an additional cysteine into the protein of interest is apossible way to circumvent this limitation and has found widespread application in nanobody functionalization.
[14a, 75] In most cases,t he cysteine has been introduced at the Cterminus of the nanobody,t hus ensuring that the conjugation site is most distal from the antigen-binding interface (Figure 8a ). Massa et al. used an engineered cysteine nanobody to produce homogeneous biomarkers for human epidermal growth factor receptor 2( HER2)-expressing cancer cells.
[14a] Along these lines,s ingle cysteine nanobodies against carbonic anhydrase IX (CAIX) and prostate-specific membrane antigen (PSMA9), labelled with an infrared dye and ar adiolabel, respectively,h ave been applied to the in vivo diagnosis of breast and prostate cancer (Figure 8b ). [75a,d] In 2012, Vugmeyster and co-workers covalently attached branched and linear polyethylene glycol (PEG) linkers to the Cterminus of single cysteine nanobodies to prolong their in vivo circulation time.
[75e] Pharmacokinetic and biodistribution profiles in three different species showed that the sitespecific attachment of PEG chains successfully protected the Figure 7 . Random labeling of nanobodies. a) NHS-activated probes/ drugs are reacted with the nucleophilic e-amine of asolvent-exposed lysine residue, resulting in heterogeneous nanobody conjugate mixtures with partly reduced binding affinities. b) The C-terminal fusion of ap oly-lysine stretch to nanobodies is intended to prevent unselective NHS-based labeling of Lysr esidues within the CDR loops responsible for antigen binding. The nanobody is depicted in gray,t he introduced functionality (e.g.,fluorophore, drug, tracer) in red. The crystal structure of aGFP-binding nanobody is used in (a) and (b) [PDB ID: 3G9A]. [17] Figure 6. FP-binding nanobodies like the GFP-binding GBP enable the combinatoriala nalysis of proteins and their interactionp artners through imaging and mass spectrometry-based proteomics. Ap rotein of interest (Protein 1) expressed as an FP fusion can be imaged using conventional methods. An anobody that binds the FP is chemicallyi mmobilized on asolid support, which facilitates enrichment of the target protein and any interacting protein (Proteins 2and 3) . Subsequent MS analysis enables the identification and assignmentofthe co-enriched interacting proteins.
nanobody by masking sites related to cellular uptake, proteolysis,and other clearance pathways (Figure 8c) . Moreover, DNA-binding polyethyleneimine-maleimide has been conjugated to asingle cysteine nanobody against MUC1-overexpressing cancer cells to selectively induce apoptosis by polyethylenimine/DNAdelivery.
[75c] However,the C-terminal attachment of cysteiner esidues often results in dimerization of the nanobodies and glutathione capping of the unpaired cysteine,t hus making an additional reduction step prior to functionalization unavoidable.
[14a] Therefore,P leiner et al. analyzed the tertiary structure of an anobody binding the Xenopus nuclear pore complex and engineered ac ysteinea t the surface of the nanobody framework region that is less prone towards capping and protein dimerization.
[14b] In general, however, introducing additional cysteines into ananobody can result in reduced expression yields. [14a, 71] Chemoenzymatic Labelling:
Ever since the bacterial biotin ligase (BirA) was repurposed to site-specifically biotinylate ap rotein of interest, different labelling methods have been developed that are built upon the reinterpretation of an aturally occurring enzyme. [76] In vivo biotinylation by BirA was one of the first chemoenzymatic methods applied to nanobodies.H ere,t he Cterminus of the nanobody is genetically fused to as hort biotin acceptor domain (BAD) and co-expressed in human cells with BirA. Thee nzyme activates biotin through monophosphorylation and transfers the biotinyl moiety to the target protein during expression. This system has been applied to generate nanobody-based ELISA and immunosensors for the rapid detection of influenza and apolipoprotein (Figure 9a) . [77] However,b eing limited to the biotinylation of proteins restricts the applicability of this method.
Tr ansglutaminases are another family of enzymes that have been adapted to site-specifically modify proteins.I n nature,t hey play an important role in the crosslinking of proteins and catalyze the formation of an isopeptide bond between the g-carbonyl amide group of glutamines and the e-amine group of lysines. [78] In principle,t ransglutaminases [17] Figure 8 . Nanobody functionalization through labelling of unpaired cysteine residues. a) Nanobodiesd onot possess free cysteine residues. Therefore, incorporating asingle cysteine residue into ananobody (mostly to the Cterminus) is an easy way to site-specifically attach ap robe or drug through cysteine-selective chemistry (shown for amaleimide-functionalizedprobe). b) Ap rostate cancer specific nanobody (antigen PSMA) containing aC-terminalu npaired cysteine was site-specifically functionalizedw ith aradiolabel by the use of maleimide chemistry.S ingle-photon emission computed tomography (SPECT)/CT images of mice bearing prostate cancer tumors in the left shoulder were taken 3h(left) and 24 h (right) after injection of the nanobody.S cale from 0to0.015 kBq (left) and 0t o0.005 kBq (right).
[75a] c) At umor necrosis factor alpha (TNF) nanobody was conjugated to linear and branched polyethylene glycol (PEG) chains through maleimide chemistry.S ubsequentpharmacokinetic experiments in mice, rats, and monkeys revealed that the branched PEG conjugates show significantly improvedi nvivo circulation time compared to linear PEG in all tested species as schematically shown in the concentration-time plot. The nanobody is depicted in gray,t he introduced functionality in red. The crystal structure of aGFP-binding nanobody is used in (a) and (c) [PDB ID:3G9A]. [17] Angewandte Chemie Reviews can target any glutamine residue within ap rotein of interest as long as it is positioned in ad isordered or highly flexible region of the biomolecule. [79] Since nanobodies do not contain such glutamine residues,t ransglutaminases were successfully applied for their site-specific modification by placing aglutamine-containing c-myc-tag (EQKLISEEDL) at the protein Cterminus (Figure 9b) . [80] Although this was only used to biotinylate nanobodies,F abs and other antigen-binding proteins have been functionalized with different entities, including fluorophores and drugs,a nd in principle,t hese findings should be applicable to nanobodies too. [80, 81] Thetranspeptidase Sortase Afrom Staphylococcus aureus specifically recognizes the consensus sequence LPXTG (Sortag) that can be placed at the Cterminus of ap rotein of interest. [82] An ucleophilic attack of the thiol at C148 on the enzyme cleaves the amide bond between glycine and threonine of the Sortag,l eading to at hioacyl intermediate.A second nucleophilic attack by an incoming glycine peptide carrying ap ayload of choice results in the site-specific functionalization of proteins through an ative amide bond. [82] [83] Moreover,S ortase Ah as been applied for the Nterminal modification of proteins and shows substantial promiscuity with respect to nucleophilic substrates. [84] Witte and co-workers used Sortase Atogenerate nanobody dimers through C-to-C fusion, as well as bispecific nanobodies against GFP and mouse class II MHC products in yields of up to 90 %. [85] In addition to that, Sortase Ah as been used to sitespecifically attach fluorophores and radiotracers for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging in vivo (Figure 10 a) . [86] In ar ecent study,S ortase Al abelling was combined with an engineered unpaired cysteine to achieve double functionalization of nanobodies and site-specifically fluorescently labelled nanobody dimers (Figure 10 b) . [87] A drawback of using Sortase At of unctionalize nanobodies is the reversibility of the amide-bond formation and the resulting need for ahigh substrate excess to drive the reaction towards completion.
Thelipoic acid ligase (LpIA) is an enzyme that recognizes a1 3a mino acid peptide tag, the lipoic acid acceptor peptide (LAP,GFEIDKVWYDKADA), and ligates lipoic acid to the side chain of al ysine residue (Figure 11 a) . [89] By introducing mutations in the lipoic acid binding pocket of the enzyme, mutant enzyme variants could be generated that accept unnatural substrates instead of lipoic acid. Thee nzyme has since been used in numerous applications to attach biotin, fluorophores,o ro ther labels to the peptide tag. In this case, [17] Figure 11 . Functionalization of nanobodies by using the lipoic acid ligase (LpIA). a) LpIA recognizes the 13 amino acid LAP tag (green) and ligates an aldehyde-containing lipoic acid derivative to the side chain of alysine residue. As ubsequent oxime-forming reaction enables site-specific functionalization of the nanobody.b )Ananobody-based activation immunotherapeutic is shown. An anti-HER2n anobody was site-specifically functionalized with adinitrophenyl (DNP) moiety using LpIA. The DNP acts as an endogenous antibody-recruiting domain, facilitatingatargeted immune response upon HER2 binding of the nanobody.The nanobody is depicted in gray,t he introducedfunctionality in red. The crystal structure of aGFP-binding nanobody is used in (a) and (b) [PDB ID:3G9A].
ap reviously generated mutant of the enzyme was used that can attach ab ioorthogonal aryl-aldehyde handle to the acceptor peptide. [90] Gray et al. applied this to the modification of an anti-HER2 nanobody with ad initrophenyl moiety. [91] By incubating HER2-positive cancer cells with the nanobody and an anti-dinitrophenyl IgG antibody,t he authors could trigger an immune response leading to antibody-dependent cytotoxicity (Figure 11 b) . Thef unctionalized nanobody serves as an immunotherapeutic that mediates between the cancer antigen and the immune system.
Recently,o ur research groups have added to the toolbox of site-specific chemoenzymatic protein functionalization [92] with Tu b-tag labeling.This is versatile method that allows the C-terminal attachment of small unnatural tyrosine derivatives using the recombinant enzyme tubulin tyrosine ligase (TTL) (Figure 12 a) . Thed erivatives carry unique chemical entities like azides,a ldehydes,a nd iodides,t hus making Tu b-tag compatible with several well-established bioorthogonal reactions.I nd etail, the TTL recognizes a1 4a mino acid recognition sequence (Tub-tag, VDSVEGEGEEEGEE) fused to the Cterminus of aprotein of interest and covalently attaches the tyrosine derivative of choice in an ATPdependent reaction. Moreover,b ased on the enlarged catalytic cavity formed by the enzyme during the catalytic cycle (Figure 12 b) , we were able to significantly broaden the substrate scope of Tu b-tag labeling. [93] This allowed us to advance the versatile two-step method to af ast one-step labelling strategy that makes use of fluorescent coumarin and biotin derivatives as TTL substrates (Figure 12 c, d ). Since the Cterminus of nanobodies is most distant from their antigenbinding region, we envisioned Tu b-tag labelling as aw ellsuited technology for nanobody functionalization. Therefore, we recombinantly expressed an umber of Tub-tagged nanobodies and generated nanobody-based immunoprecipitation tools and super-resolution probes with minimal linkage errors.
[92a, 93] 
Amber Suppression
Another prominent technology for the site-specific labelling of proteins is amber suppression. [94] Here,a nu nnatural amino acid carrying au nique chemical entity (a bioorthogonal group) is incorporated into ar andom site within the sequence of the target protein using an engineered expression machinery.I nasecond step,apayload of choice is sitespecifically attached to the bioorthogonal group.O ne of the major advantages of amber suppression is the high variety of unnatural amino acids that can be incorporated using the system. [95] Recently,t he unnatural amino acid AmAzZLys was incorporated into an anobody against the epidermal growth factor receptor (EGFR). [96] AmAzZLys is al ysine derivative that contains ab enzylic amine and azide,w hich allowed subsequent double functionalization of the nanobody with af luorophore and a5kDa PEG chain (Figure 13 a) . Moreover,t he benzylic azide was used to perform photoinduced crosslinking to EGFR upon antigen binding (Figure 13 b) . However,amber suppression is technically demanding and results in as ignificantly lower expression yield compared to the wild-type nanobody,thus limiting the usage of amber suppression for nanobody functionalization.
[96] Figure 12 . Tub-tag labelling for the functionalization of nanobodies and recombinant antigen-binding proteins. a) Versatile two-step labelling of nanobodies. TTL-mediated incorporationo ftyrosine derivatives containing chemical reporters enables successivec onjugation to afunctional probe (red) using abioorthogonal reaction. b) The TTL (PDB ID:4IHJ) [88] forms an extended cavity during the catalytic cycle. This cavity allows lead to abroad substrate tolerance. c) Fluorescent or biotinylateds ubstrates of TTL enable the efficient one-stepl abelling of biomolecules. d) Substrates of TTL include ortho-and para-functionalized tyrosine derivatives, fluorescent coumarin amino acids. and large biotinylatedt yrosine derivatives. The nanobody is depicted in gray,t he introducedfunctionality in red, and TTL in purple. The crystal structure of aGFP-binding nanobody is used in (a) and (c) [PDB ID:3G9A]. [17] Angewandte Chemie
Reviews Expressed Protein Ligation and Protein trans-Splicing
Expressed protein ligation (EPL) is at echnology that is based on the naturally occurring splicing of proteins. [97] A protein of interest is expressed as af usion with am utated intein that generates ah ighly reactive C-terminal thioester upon activation with areducing agent like 2-mercaptoethanol or dithiothreitol. In afollowing ligation reaction to apeptide carrying an N-terminal cysteine, an ew peptide bond is generated through S-to-N acyl transfer. [97] Most of the time, the cysteine peptide is synthesized by solid-phase peptide synthesis (SPPS), which enables the straightforward incorporation of functional probes and payloads.Therefore,EPL has broad application for the site-specific functionalization of proteins and nanobodies (Figure 13 c) .
[74b] An alkyne-modified cysteinew as recently incorporated to av ascular cell adhesion molecule 1( VCAM-1)-binding nanobody by EPL and further modified with biotin by as ubsequent coppercatalyzed click reaction. [98] Optimizing the expression and ligation protocol allowed the generation of decent amounts of nanobody with high functionalization yields of up to 100 %. In another study,EPL was used for the double functionalization of avascular-tumortargeting nanobody with polymersomes for drug delivery and biotin. [100] While EPL facilitates the C-terminal functionalization of proteins,B achmann et al. recently made use of the GOS-TerL intein and ap rotein trans-splicing reaction to functionalize aG FP-binding nanobody with as ynthetic fluorophore at its Nterminus. [101] However,w hen choosing EPL or intein-fusion strategies,r efolding from inclusion bodies is often required to achieve functional proteins, which significantly increases experimental effort. [102] In recent years,h uge efforts have been made to broaden the toolbox of conjugation methods for the functionalization of nanobodies and other antigen-binding proteins.W hile all of the methods discussed in this review have their pros and cons,t he methodological versatility enables the interested scientist to pick one of the validated techniques according to the requirements of the individual application. Nevertheless, to fully maintain protein function, the site-specific C-terminal functionalization of nanobodies has proven beneficious compared to unselective labeling strategies.Owing to reduced engineering effort and high conjugation yields,the labeling of unpaired cysteine residues and chemoenzymatic functionalization strategies are particularly suitable for achieving this goal.
In addition to the functionalization of nanobodies and other binders,t heir subsequent cellular delivery is of high interest to the scientific community.Recent achievements are discussed in the next section.
Cellular Delivery of Small Antigen-Binding Proteins
Thed irect cellular delivery of nanobodies and antigenbinding proteins is al ong-standing goal in cell biology and medicine,s ince it would offer an on-integrative way to analyze and manipulate cellular processes,p rotein-protein interactions,a nd protein function. [103] Therefore,i ntense research has been invested within recent decades to develop general methods to achieve this goal. [11c, 104] In principle, intracellular functional antigen-binding proteins can be obtained by transfecting cells,f or example with the use of intrabodies that are optimized for intracellular expression.
[11b] Figure 13 . Methods that have been used for the site-specific labelling of nanobodies( gray). a) Amber suppressionw as used to install the amino acid AmAzZLys into ananobody.T he benzylic amine of the unnaturala mino acid was reacted with an aldehyde-containing PEG chain and the benzylic azide with adibenzocyclooctyl fluorophore, resulting in adoubly functionalized nanobody.b)AmAzZLys was incorporated into ananobody targeting the epidermal growth factor receptor (EGFR, PDB ID:3P0Y [99b] ). The amino group was used for fluorescentlabelling, while the azide was activated by UV irradiation,a nd photo-cross-linking between the nanobody and EGFR was performed. c) Expressed protein ligation (EPL) shown for the C-terminal functionalization of nanobodies. The respective nanobody is expressed as an intein fusion (intein shown in turquoise, PDB ID: 4GIG
[99a] ). Activation with areducing agent like DTT or mercaptoethanol results in the formation of ahighly reactive thioester.T ransthioesterification initiated by nucleophilic attack of acysteine-containing probe, followed by aS-to-N acyl transfer results in the formation of astable amide bond and the site-specific functionalizationo fthe nanobody.The nanobody is depicted in gray,t he introducedfunctionality in red, EGFR in blue, and intein in turquoise.T he crystal structure of aGFP-bindingnanobody is used in (a), (b), and (c) [PDB ID:3 G9A]. [17] Angewandte Chemie Reviews However,t he functional cytosolic expression of binders remains challenging and their functionalization with small molecules like affinity tags,f luorophores,a nd drugs is not possible when using such techniques. [11b,c,104a, 105] In this sense,t he delivery of functional antigen-binding proteins into living cells would vastly expand the methodological repertoire of antigen-binding proteins for intracellular use. [107] Supercharged proteins are ac lass of engineered proteins that are able to penetrate mammalian cells. [108] In 2016, Bruce et al. made use of this concept and successfully engineered nanobodies against GFP,HER2, and b-lactamase in order to make them cell-permeable. [109] To accomplish this, they "resurfaced" the nanobodies,t hat is,m utated several amino acid residues on the surface of the proteins to basic residues,resulting in net positive charges of + 14 and + 15 for the nanobodies overall. These polycationic nanobodies could then penetrate cells (incubated with 250-500 nm nanobody) and showed localization in the cytosol and not in endosomes (Figure 14 a) . While they demonstrated that the engineering does not impact the nanobody structure or the ability of the GFP-binding nanobody to bind its antigen, it is difficult to estimate what effect the high net charge could have on localization and antigen binding in ag eneralistic manner. Besides making the proteins directly cell-permeable,delivery of proteins can also be achieved using biophysical methods like microinjection and electroporation [110] and by using one of the increasingly important carrier-based delivery systems.
[105a] In principle,t he carrier-based delivery of cargo to cells follows two main pathways;e ndocytosis-dependent uptake (Figure 14 b) and the transduction across the cell membrane (Figure 14 c) .
Endocytosis is the predominant pathway described for the delivery of biomolecules. [111] Here,e xtracellular macromolecules pass through the plasma membrane via encapsulation in vesicles and become trapped in endosomes,which can lead to lysosomal degradation. To be available inside the cell, the biomolecule then needs to escape from the endosome.T his can be achieved through lipid or osmotic pressure mediated destabilization of the membrane or translocation of the cargo through transmembrane pores. [111] [112] In 2016, Chiu and coworkers developed large-pore mesoporous silica nanoparticles (MSNs) that are functionalized with nitrilotriacetic acid (NTA) groups at the internal surface (Figure 14 d) . [113] Activation of the complex with various metal ions enabled the covalent attachment of aH is 6 -tagged GFP-chromobody. Incubation of living cells with these complexes at ac oncentration of 25 nm resulted in endocytic uptake and endosomal entrapment of the conjugate.A lthough as mall amount of chromobody was able to escape the endosomes (1-2 %), probably due to aproton sponge effect generated by the His 6 -tag, the use of endosomal-escape triggers like fusogenic peptide INF7, acidity,D MSO,o rc hloroquine was necessary to obtain adecent amount ($17 %) of chromobody within the cytosol. Importantly,i ntracellular co-localization of the Figure 14 . Depiction of delivery mechanisms that have been used for the cellular uptake of nanobodies. Nanobodiesh ave been delivered into cells through the use of a) charged surface mediated transduction, b) endocytosis, or c) cyclic cell-penetrating peptides (CPPs). The nanobody is depicted in gray,the introducedf unctionality in red. d) Thiol-containingmesoporouss ilica nanoparticles( MSNs) were conjugatedt oamaleimidefunctionalized nitrilotriacetic acid (NTA) linker.Activation with ametal ion (shown for Ni)facilitated binding of aHis 6 -chromobody.T he MSNchromobody complex showed endosomal entrapment upon cellular incubation, thus necessitating endosomal escape triggers like the peptide INF7 to enable cytosolic distribution of the chromobody.e)Acell delivery system based on the anthrax lethal toxin. Recombinanta ntigen-binding proteins (shown for amonobody) are expressed as af usion with the 30 kDa N-terminald omain of the toxin enzyme lethal factor (LF N ). The protective-antigen (PA)-based pore-formingtransporter (PA oligomers shown in green) is bound to ahost-cell receptor.The binder-LF N forms acomplex with the transporter (step 1) and endocytosis is initiated (step 2and 3). Due to the acidic environment in the endosome, the PA oligomers form atransmembrane pore, unfolds the binder-LF N fusion protein and initiates its translocation to the cytosol (step 4). The nanobody is depicted in gray,R FP (PDB ID:1 GGX [106] )i nr ed, and the monobody in blue (PDB ID:3RZW [18] ). The crystal structure of aGFP-binding nanobody is used in (a), (b), (c), and (d) [PDB ID:3 G9A]. [17] Angewandte Chemie Reviews chromobody with its antigen confirmed full functionality of the antigen-binding protein, and the MSN-NTAc omplex allows combination with any His-tagged protein. One year later, Rçder et al. combined fluorescently labelled nanobodies (via NHS-esters) with an umber of different nanoparticle-forming oligoaminoamides equipped with succinoyl tetraethylene pentamine units that trigger endosomal release. [114] Incubation of the encapsulated nanobodies with HeLa cells at 3.6 mm concentrations resulted in either receptor-specific or non-specific endocytic uptake.T hrough this strategy,t hey were able to achieve high co-localization with the antigen and intracellular availability of the nanobody of up to 60 %. Nevertheless,e ndosomal escape remained ab ottleneck, as indicated by as ignificant amount of nanoparticles entrapped in cellular vesicles.
In the past few years,ar eceptor-dependent delivery system based on the anthrax lethal toxin has been developed and applied for the delivery of anumber of biomolecules. [115] In nature,protective antigen (PA) binds to anthrax receptors on human cells and oligomerizes to form heptamers or octamers.O nce lethal factor (LF) binding occurs,t he whole complex is endocytosed. Subsequently,the acidic milieu of the endosomes initiates ar earrangement of PA ,l eading to the formation of aP Ap ore in the membrane that allows translocation of the LF to the cytosol. Liao et al. made use of this system and chemoenzymatically attach LF to an affibody,aDARPin, and am onobody by using Sortase A (Figure 14 e) . [116] In this way,t hey were able to achieve delivery of these recombinant binders to the cytosol with maintained antigen-binding properties (cells were incubated with pm-nm concentrations of recombinant binder and 20 nm PA ). Nevertheless,t ranslocation through the PA pore requires protein unfolding and subsequent refolding,t hus limiting this approach to antigen-binding proteins that are readily folded within the reductive environment of the cytosol. In this sense,m ost of the aforementioned examples for the cellular delivery of nanobodies and antigen-binding proteins require endosomal escape mechanisms that constitute am ajor bottleneck for addressing intracellular antigens in living cells.
Theuse of cell-penetrating peptides (CPPs) might circumvent this limitation since they have been shown to enable the direct cellular uptake of functional full-length proteins. [117] Therefore,the generation of cell-penetrating antigen-binding proteins by CPP fusion is the next logical step to fulfill the goal of immediate bioavailability and antigen binding.Herce and Schumacher et al. recently made use of this concept and ligated linear and cyclic HIV-derived TATand deca-arginine (R 10 )peptides to the Cterminus of two different GFP-binding nanobodies by EPL (Figure 15 a) . [118] Subsequent studies revealed that the conjugates produced transduction rates of up to 95 %i nc ells from different cell lines when incubated with low mm concentrations (10 mm). Moreover,t he uptake initiated by R 10 peptides is up to three times increased compared to that initiated by TAT, and cyclization of the peptides further increases uptake efficiency. Based on these findings,c yclic R10 peptides are most suitable for the generation of cell-permeable nanobodies.c R10 conjugates were then applied for the co-transport of GFP and GFP fusion proteins with as ize of up to 83 kDa, including the therapeutically relevant Mecp2 protein. [119] Moreover,t he cell-permeable nanobodies have been used to visualize protein-protein interactions in living cells by slightly adopting the previously published three-hybrid assay. [48] These experiments show that cell-permeable nanobodies are powerful tools for cell biology and the delivery of recombinant and Figure 15 . Charge-induced membrane transduction of nanobodies initiated by cell penetrating peptides (CPPs). a-b) Expressed protein ligation (EPL) of nanobodies was used to site-specifically conjugateC PPs through a) astable amide bond to give non-cleavable nanobody-CPP conjugates or b) acleavable disulfide that gets reduced within the reductive cytosolic environment( cleavable and fluorescentn anobody-CPP). c) Incubation with different cell lines revealede fficient uptake in up to 95 %o fthe cells when incubated with low mm concentrations. Upon incubation of the Cy5-labelled cleavable nanobody with cells, the conjugatec rosses the cellular membrane into the cytosol, CPP cleavage is initiated, and the fluorescently labelled nanobody binds its nuclear antigen GFP. The nanobody is depicted in gray,G FP in green, and Cy5inred. The crystal structure of aGFP-binding nanobody is used in (a), (b), and (c) [PDB ID:3 G9A].
therapeutically relevant proteins.S ince arginine-rich CPPs localize to the nucleolus and bind to negatively charged RNA, addressing targets within the cytosol requires the rapid cleavage of the CPP after cellular uptake.T herefore,H erce and Schumacher et al. site-specifically conjugated af luorophore via EPL to the Cterminus of the nanobody and used the cysteine created at the EPL junction for linkage of the CPP via ad isulfide (Figure 15 b) . Uptake studies and fluorescence microscopy revealed efficient internalization of the Cy5-labelled nanobody without nucleolar enrichment, thus indicating reductive CPP cleavage within cytosol (Figure 15 c) . This conjugate was used for the visualization of antigens in living cells,a nd constitutes av ery promising tool for intracellular immunostaining and immunomanipulation.
Conclusion
Ever since their discovery,n anobodies have emerged as powerful antigen binders that, together with conventional antibodies and other classes of antigen-binding proteins,form aversatile toolbox for biochemistry,cell biology,and beyond. Nanobodies are characterized by their small size,i ncreased solubility and stability compared to other antigen-binding proteins,and enlarged CDR loops that open the door towards previously inaccessible antigens.T he fusion of nanobodies to fluorescent proteins initiated the generation of highly sophisticated, functional binders that have been further advanced through conjugation to organic fluorophores,t racers,a nd drugs,a sw ell as the immobilization of nanobodies to solid supports.W hile such conjugates were originally synthesized using NHS chemistry,r esulting in heterogeneous mixtures, strategies for the site-specific functionalization of nanobodies have been developed, leading to products with improved biophysical properties.N ew approaches for the cellular delivery of functional antigen-binding proteins allows their use within the cellular environment, which constitutes amajor step in live-cell immunolabelling and antigen manipulation. Taken together, the versatility of antigen-binding proteins, methods for their functionalization, and strategies for their cellular delivery forms apowerful basis for the generation of next-generation diagnostics and therapeutic tools with striking properties.
